OLPRINONE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H10N4O
Molecular Weight	250.2554
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=C(C=C(C#N)C(=O)N1)C2=CN3C=CN=C3C=C2

InChI

InChIKey=JPAWFIIYTJQOKW-UHFFFAOYSA-N

InChI=1S/C14H10N4O/c1-9-12(6-11(7-15)14(19)17-9)10-2-3-13-16-4-5-18(13)8-10/h2-6,8H,1H3,(H,17,19)

HIDE SMILES / InChI

Molecular Formula	C14H10N4O
Molecular Weight	250.2554
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/2566308
Curator's Comment: description was created based on several sources, including http://www.eisai.jp/medical/products/di/EPI/COR_A_EPI.pdf

Olprinone (INN) is a cardiotonic agent, is used for treatment acute heart failure. It has been marketed in Japan since 1996. The main mechanism of action of olprinone hydrochloride hydrate is selective inhibition of PDE III specific to cAMP. It is considered that this action causes an increase in intracellular cAMP levels and peak Ca2+ levels, thereby increasing myocardial contractility.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Phosphodiesterase 3 60 Target ID: CHEMBL2094125 Sources: http://www.ncbi.nlm.nih.gov/pubmed/2566308	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Acute heart failure 9 Sources: http://www.eisai.jp/medical/products/di/EPI/COR_A_EPI.pdf	Primary		Approved 8429	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
The effects of olprinone (a phosphodiesterase III inhibitor) on hepatic vascular bed in a porcine model of endotoxemia.	2001 Mar	11226100
Inhaled olprinone improves contractility of fatigued canine diaphragm.	2002 Mar	11990275
Olprinone, a phosphodiesterase III inhibitor, reduces gut mucosal injury and portal endotoxin level during acute hypoxia in rabbits.	2003 Jun	12766650
Toborinone and olprinone, phosphodiesterase III inhibitors, inhibit human platelet aggregation due to the inhibition of both calcium release from intracellular stores and calcium entry.	2004	15127258
[Successful anesthetic management of patients with poor ventricular function using the phosphodiesterase III inhibitor, olprinone, during major cardiovascular procedures].	2004 Feb	15011421
[Application of a PDE III inhibitor, olprinone, for fast track pediatric cardiac surgery].	2004 Mar	15071874
Effects of olprinone on hepatosplanchnic circulation and mitochondrial oxidation in a porcine model of endotoxemia.	2005	16261466
Effects of phosphodiesterase-III inhibitors on sevoflurane-induced impairment of rat diaphragmatic function.	2005 Jul	15954966
Differential pharmacologic sensitivities of phosphodiesterase-3 inhibitors among human isolated gastroepiploic, internal mammary, and radial arteries.	2005 Oct	16192501
[Effects of olprinone hydrochloride in patients undergoing off-pump coronary artery bypass grafting].	2006 Feb	16491891
Effects of dopamine and olprinone on ventricular energetics in sevoflurane-induced acute left ventricular depression in dogs.	2006 Jun	16750736
Chemical-genetic profiling of imidazo[1,2-a]pyridines and -pyrimidines reveals target pathways conserved between yeast and human cells.	2008 Nov	19043571
[The effect of PDEIII inhibitors and colforsin daropate on hypoxic pulmonary vasoconstriction in rabbit lungs].	2008 Nov	19039966
Pharmacological preconditioning in type 2 diabetic rat hearts: the roles of mitochondrial ATP-sensitive potassium channels and the phosphatidylinositol 3-kinase-Akt pathway.	2009 Aug	19597978
The effects of the phosphodiesterase inhibitor olprinone on global cerebral ischemia.	2010 Mar 1	20042441
Olprinone attenuates the acute inflammatory response and apoptosis after spinal cord trauma in mice.	2010 Sep 7	20830289

Patents

Sample Use Guides

In Vivo Use Guide

intravenously at a dose of 10 µg/kg of olprinone hydrochloride hydrate, gradually over 5 min, and then drip-infused intravenously at a rate of 0.1 - 0.3 µg/kg/min

Route of Administration: Intravenous

In Vitro Use Guide

E-1020 (Olprinone) may improve diastolic function as well as systolic function in failing hearts. Effects of E-1020, on intracellular calcium transients were compared with those of isoproterenol (ISO) in isolated single myocytes from failing hearts secondary to pulmonary hypertension induced by monocrotaline injection. Myocytes were isolated by enzyme digestion using a Langendorff apparatus. Changes in intracellular calcium concentrations ([Ca2+]i) were recorded using a fura-2 fluorescence microscopic technique.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:50:03 GMT 2023` Edited by `admin` on `Sat Dec 16 17:50:03 GMT 2023`
Record UNII	4Y8BMI9YGC
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OLPRINONE

Official Name

English

Olprinone [WHO-DD]

Common Name

English

1,2-DIHYDRO-5-IMIDAZO(1,2-.ALPHA.)PYRIDIN-6-YL-6-METHYL-2-OXONICOTINONITRILE

Common Name

English

LOPRINONE [MI]

Common Name

English

olprinone [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C744